Table 1.

Overview of the reproductive and clinical outcomes.

Number of Patients	Allocation	Reproductive Outcomes	Dose Concentration	Clinical Outcomes	Reference
n = 701	Cycle 2 n = 252; follitropin delta n = 261; follitropin alfa Cycle 3 n = 95; follitropin delta n = 93; follitropin alfa	Cycle 2 10.2 ± 5.2 vs. 9.9 ± 4.9; follicles ≥ 12 mm 9.2 ± 4.8 vs. 8.6 ± 4.3; oocytes retrieved 56.8 ± 23.5 vs. 52.6 ± 24.3; fertilization rate 5.1 ± 3.3 vs. 4.3 ± 2.8; total embryos D3 3.9 ± 3.1 vs. 3.3 ± 2.4; good quality embryos D3 2.8 ± 2.4 vs. 2.4 ± 2.1; total blastocysts D5 1.4 ± 1.7 vs. 1.2 ± 1.6; good quality blastocysts D5 Cycle 3 8.9 ± 4.5 vs. 9.8 ± 4.8; follicles ≥ 12 mm 8.3 ± 4.0 vs. 8.9 ± 4.2; oocytes retrieved 56.3 ± 20.6 vs. 49.7 ± 24.9; fertilization rate 4.4 ± 2.4 vs. 4.4 ± 3.3; total embryos D3 3.2 ± 2.2 vs. 3.3 ± 3.0; good quality embryos D3 2.2 ± 1.8 vs. 2.4 ± 2.3; total blastocysts D5 1.2 ± 1.5 vs. 1.2 ± 1.8; good quality blastocysts D5	Cycle 2 18 µg—max dose 225 IU—max dose; 75 IU adjustments, up to max 450 IU Cycle 3 24 µg—max dose 300 IU—max dose; 75 IU adjustments, up to max 450 IU	Cycle 2 n = 82 (32.5%) vs. n = 79 (30.3%)—clinical pregnancy rate n = 74 (29.4%) vs. n = 71 (27.2%)—vital pregnancy rate n = 70 (27.8%) vs. n = 67 (25.7%)—ongoing pregnancy rate n = 69 (27.4%) vs. n = 66 (25.3%)—live birth rate n = 69 (27.4%) vs. n = 66 (25.3%)—live birth rate at 4 weeks n = 5 (7.1%) vs. n = 2 (3.0%)—multiple pregnancy rate Cycle 3 n = 31 (32.6%) vs. n = 30 (32.3%)—clinical pregnancy rate n = 26 (27.4%) vs. n = 27 (29.0%)—vital pregnancy rate n = 26 (27.4%) vs. n = 26 (28.0%)—ongoing pregnancy rate n = 25 (26.3%) vs. n = 25 (26.9%)—live birth rate n = 25 (26.3%) vs. n = 25 (26.9%)—live birth rate at 4 weeks n = 8 (30.8%) vs. n = 10 (38.5%)—multiple pregnancy rate	[19]
n = 158	n = 37; follitropin delta n = 40; follitropin delta n = 40; follitropin delta n = 41; follitropin beta	7.0 ± 4.1 vs. 9.1 ± 5.6 vs. 11.6 ± 5.6 vs. 11.0 ± 4.7; oocytes retrieved in all patients 5.3 ± 3.7 vs. 5.6 ± 3.5 vs. 9.5 ± 3.0 vs. 9.3 ± 4.3; oocytes retrieved in low AMH stratum 7.9 ± 4.1 vs. 11.2 ± 5.6 vs. 12.9 ± 6.4 vs. 11.8 ± 4.7; oocytes retrieved in high AMH stratum 3.2 ± 2.2 vs. 4.4 ± 3.1 vs. 5.9 ± 3.6 vs. 5.7 ± 3.8; fertilized oocytes in all patients 2.5 ± 2.2 vs. 2.9 ± 2.3 vs. 3.9 ± 2.3 vs. 5.4 ± 3.2; fertilized oocytes in low AMH stratum 3.5 ± 2.2 vs. 5.3 ± 3.2 vs. 7.0 ± 3.7 vs. 5.9 ± 4.1; fertilized oocytes in high AMH stratum 21.4 ± 8.5 vs. 23.6 ± 9.5 vs. 28.5 ± 10.2 vs. 27.9 ± 10.0; follicular volume in all patients 19.9 ± 8.4 vs. 18.9 ± 6.7 vs. 23.2 ± 6.3 vs. 24.7 ± 9.1; follicular volume in low AMH stratum 22.1 ± 8.6 vs. 26.4 ± 10.0 vs. 31.7 ± 10.7 vs. 29.6 ± 10.2; follicular volume in high AMH stratum	6 µg 9 µg 12 µg 150 IU	n = 9 (24%) vs. n = 8 (20%) vs. n = 13 (33%) vs. n = 8 (20%)—clinical pregnancy rate per started cycle n = 9 (35%) vs. n = 8 (26%) vs. n = 13 (41%) vs. n = 8 (26%)—clinical pregnancy rate per cycle with transfer n = 7 (19%) vs. n = 8 (20%) vs. n = 10 (25%) vs. n = 6 (15%)—vital pregnancy rate per started cycle n = 7 (27%) vs. n = 8 (26%) vs. n = 10 (31%) vs. n = 6 (19%)—vital pregnancy rate per cycle with transfer n = 6 (16%) vs. n = 7 (18%) vs. n = 10 (25%) vs. n = 6 (15%)—ongoing pregnancy rate per started cycle n = 6 (23%) vs. n = 7 (23%) vs. n = 10 (31%) vs. n = 6 (19%)—ongoing pregnancy rate per cycle with transfer n = 6 (16%) vs. n = 7 (18%) vs. n = 9 (23%) vs. n = 6 (15%)—live birth rate per started cycle n = 6 (23%) vs. n = 7 (23%) vs. n = 9 (28%) vs. n = 6 (19%)—live birth rate per cycle with transfer n = 6 (16%) vs. n = 7 (18%) vs. n = 9 (23%) vs. n = 6 (15%)—live birth rate at 4 weeks per started cycle n = 6 (23%) vs. n = 7 (23%) vs. n = 9 (28%) vs. n = 6 (19%)—live birth rate at 4 weeks per started cycle	[20]
n = 403	n = 297; follitropin alfa or beta n = 106; follitropin delta	8.42 (SD 4.64) vs. 7.41 (SD 3.43); mean no. of follicles ≥ 15 mm 3.94 (SD 2.14) vs. 3.60 (SD 1.87); mean no. of follicles ≥ 18 mm 1.47 (SD 1.23) vs. 1.41 (SD 1.13); mean no. of follicles ≥ 20 mm 12.3 (SD 7.7) vs. 10.4 (SD 6.1); mean no. of oocytes retrieved 0.760 (SD 0.207) vs. 0.732 (SD 0.240); proportion of normal fertilization	1951 IU (SD 849) 132 µg (SD 245)	35.3% vs. 38.7%—clinical pregnancy rate per fresh transfer cycles D3 37.6% vs. 38.5%—clinical pregnancy rate per fresh transfer cycles D5	[21]
n = 153	n = 78; follitropin delta n = 75; follitropin alfa	follicles ≥ 12 mm 2.5 ± 2.9 vs. 4.0 ± 4.0; stimulation D6 12.1 ± 7.0 vs. 18.3 ± 7.0; end of stimulation follicles ≥ 17 mm 5.2 ± 3.6 vs. 7.7 ± 4.9; end of stimulation 9.3 ± 6.7 vs. 17.9 ± 8.7; oocytes retrieved per started cycle 10.3 ± 6.2 vs. 17.9 ± 8.7; oocytes for subjects with oocyte retrieval 3.2 ± 2.9 vs. 5.9 ± 5.1; blastocysts D5	12 µg—no limit min dose 150 IU (11 µg); 75 IU adjustments	29.5% vs. 25.3%—vital pregnancy rate 28.2% vs. 24.0%—ongoing pregnancy rate	[22]
n = 347	n = 170; follitropin delta n = 177; follitropin beta	9.3 ± 5.4 vs. 10.5 ± 6.1; oocytes retrieved 7.2 ± 3.7 vs. 7.0 ± 3.4; oocytes retrieved when AMH < 15 pmol/L 10.8 ± 5.9 vs. 12.9 ± 6.4; oocytes retrieved when AMH ≥ 15 pmol/L 3.1 ± 2.7 vs. 4.2 ± 3.4; blastocysts D5	6 µg—min dose-12 µg—max dose 150 IU (15 µg); 75 IU adjustments, up to max 375 IU	n = 43 (25.3%) vs. n = 42 (23.7%)—clinical pregnancy rate per started cycle n = 43 (31.9%) vs. n = 42 (29.8%)—clinical pregnancy rate per cycle with transfer n = 40 (23.5%) vs. n = 34 (19.2%)—ongoing pregnancy rate per started cycle n = 40 (29.6%) vs. n = 34 (24.1%)—ongoing pregnancy rate per cycle with transfer n = 40 (23.5%) vs. n = 33 (18.6%)—live birth rate per started cycle n = 40 (29.6%) vs. n = 33 (23.4%)—live birth rate per cycle with transfer	[23]
n = 1009	n = 499; follitropin delta n = 510; follitropin alfa	10.0 ± 6.1 vs. 12.4 ± 7.3; oocytes retrieved in all patients 64 ± 23 vs. 64 ± 21; fertilization rate in all patients 7.0 ± 4.6 vs. 8.7 ± 5.5; embryos D3 in all patients 9.6 ± 5.3 vs. 7.6 ± 3.5; oocytes retrieved when AMH < 15 pmol/L 66 ± 22 vs. 67 ± 22; fertilization rate when FAMH < 15 pmol/L 6.8 ± 3.7 vs. 5.6 ± 2.9; embryos D3 when AMH < 15 pmol/L 10.1 ± 6.3 vs. 13.8 ± 7.5; oocytes retrieved when AMH ≥ 15 pmol/L 63 ± 23 vs. 63 ± 21; fertilization rate when AMH ≥ 15 pmol/L 7.0 ± 4.8 vs. 9.6 ± 5.7; embryos D3 when AMH ≥ 15 pmol/L	6 µg—min dose-12 µg—max dose 150 IU (11 µg); 75 IU adjustments, up to max 450 IU	n = 180 (36.1%) vs. n = 159 (31.2%)—clinical pregnancy rate n = 156 (31.3%) vs. n = 131 (25.7%)—ongoing pregnancy rate n = 156 (31.3%) vs. n = 126 (24.7%)—live birth rate n = 156 (31.3%) vs. n = 126 (24.7%)—live birth rate at 4 weeks	[24]
n = 360	-	11.2 (±6.7); no. of oocytes 69.1 (±25); rate of fertilization in two-pronuclear/metaphase II 55.5 (±24.5); rate of fertilization in two-pronuclear/oocyte 81.7 (±18.1); rate of fertilization in metaphase II/oocyte	8.7 µg—median 9.0 µg (±2.3 SD)—mean	n = 109 (38.2%)—clinical pregnancy rate in the first fresh cycle with an ET 36.8%—clinical pregnancy rate in the fresh transfer cycle with a SET 49.4%—cumulative clinical pregnancy rate for the first stimulation cycle including cryopreservation cycles 9.3%—spontaneous miscarriage rate per transfer for the first fresh cycle 13.2%—spontaneous miscarriage rate per transfer for the first stimulation cycle including cryopreservation cycles 20.7%—miscarriage rate per clinical pregnancy in the first fresh cycle 23.4%—miscarriage rate per clinical pregnancy in the first stimulation cycle including cryopreservation cycles	[25]
n = 619	n = 104; placebo n = 104; follitropin delta n = 101; follitropin delta n = 99; follitropin delta n = 107; follitropin delta n = 104; follitropin delta	12.7 vs. 11.8 vs. 11.6 vs. 11.0 vs. 11.4 vs. 10.6; follicles ≥ 12 mm 5.2 vs. 5.3 vs. 5.1 vs. 5.3 vs. 5.3 vs. 4.9; follicles ≥ 17 mm 12.5 vs. 10.6 vs. 10.7 vs. 10.6 vs. 11.3 vs. 9.7; oocytes retrieved 9.7 vs. 8.2 vs. 8.3 vs. 8.0 vs. 8.4 vs. 7.3; oocytes metaphase II 7.4 vs. 6.0 vs. 6.1 vs. 5.5 vs. 5.9 vs. 5.1; oocytes fertilized 7.4 vs. 5.9 vs. 6.1 vs. 5.5 vs. 5.9 vs. 5.1; embryos D3 5.3 vs. 4.0 vs. 4.6 vs. 3.6 vs. 4.2 vs. 3.5; blastocysts D5 3.3 vs. 2.2 vs. 3.0 vs. 2.2 vs. 2.6 vs. 2.1; good quality blastocysts D5	1 µg 2 µg 4 µg 8 µg 12 µg	42.9% vs. 28.4% vs. 30.1% vs. 41.3% vs. 40.3% vs. 35.3%—vital pregnancy rate 42.9% vs. 28.4% vs. 29.1% vs. 39.2% vs. 37.4% vs. 30.4%—ongoing pregnancy rate	[26]

SD—standard deviation, ET—embryo transfer, SET—single embryo transfer.